SelectScience
Join Free
Accelerating Science
NewsLife Sciences

Sigma® Life Science Introduces World's First P53 Knockout Rat

Merck
19 Apr 2010
Sarah Sarah
Marketing / Sales

Product news

Sigma® Life Science introduces the world’s first p53 ‘knockout’ rat model, an important development that is expected to, due to the rat’s closer physiological and metabolic similarity to humans, significantly improve timelines for carcinogenicity screening and reduce time to market for therapeutics.

The p53 model, being developed through Sigma Advanced Genetic Engineering (SAGE™) Labs, a Sigma® Life Science initiative, offers the potential for faster and more accurate predictions of how anti-cancer therapeutics work in humans and seeks to increase the understanding of this critical gene. Further characterization of this model is expected to lead to a more comprehensive knowledge of how cancers begin and proliferate. Research applications include early Carcinogenicity screening, Chemopreventive and Chemotherapeutic screening, and p53 pathway studies.

“Over the past twelve months, SAGE Labs has been developing novel rat models, in which specific genes associated with defined disease conditions are deactivated or knocked-out, for use in disease research, especially in areas where the existing mouse models poorly mimic human disease,” said Dr. Edward Weinstein, director of SAGE Labs. “The addition of the p53 model extends our offering into oncology research and builds upon our existing portfolio, which targets applications across a number of fields including physiology, endocrinology, neurology and toxicology. Using our propriatary CompoZr™ Zinc Finger Nuclease platform, we are able to develop mouse or rat models without the need for embryonic stem cells. This enables us to create founder animals in about four to five months, which is about a third of the time it would take using a traditional approach.”

p53 is a tumor suppressor protein encoded by the TP53 gene and is one of the most widely studied cancer-related genes. Its role in the regulation and stabilization of cell cycle, thus preventing genome mutation, is observed among a wide variety of multicellular organisms, including humans, rodents, frogs and fish. Homozygous rats deficient in the p53 protein are expected to be prone to spontaneous tumors and will be valuable for in vivo screening of carcinogenicity, as well as studying chemopreventive and therapeutic treatment.

The colony of p53 knockout rats is currently being expanded and it is anticipated that cohorts of homozygous p53 knockout animals will be available to ship beginning in July 2010.

Links

MerckCompany website

Tags

Genome AnalysisGenomics, the study of genomes, includes functional genomics, evolutionary genomics and comparative genomics. There are many genomic technologies such as DNA sequencing of whole genomes, computational biology and bioinformatics. DNA and nucleic acids must be isolated and concentrated from cells for analysis with kits, automated analyzers and software. Other useful technologies for studying genomics include PCR, microarrays and electrophoresis.High-Throughput ScreeningHigh-throughput screening (HTS) is an automated drug discovery technique for identification of active compounds against a compound library. Use HTS readers and integrated assay preparation / analysis workstations to screen your compounds. Identify active compounds against various HTS libraries, including membranes, proteins and peptides and HTS cell lines. Find the best high-throughput screening products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Process ChemistryProcess chemistry is an important stage of drug development for scaling-up drug production or chemical synthesis reactions. It is useful for optimizing economical and efficient drug production. Process chemistry uses reactors and pump systems as well as reagents, standards and buffers.High-Content ScreeningHigh-content screening (HCS), also known as high-content analysis (HCA), is a high-throughput technique used in drug discovery to identify substances that alter the phenotype of cells. HCS uses fluorescent microscopic imaging and automated image analysis to investigate cellular events such as apoptosis, cell viability, GPCR activation, oxide production, neurite outgrowth, and cell signaling. Find the best fluorescent labeling reagents, cellular assays, and high-content imaging systems in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.

Related articles

Sigma® Life Science Introduces World's First P53 Knockout Rat